Skip to main content
. Author manuscript; available in PMC: 2021 May 27.
Published in final edited form as: J Hepatol. 2020 Mar 10;73(1):94–101. doi: 10.1016/j.jhep.2020.02.033

Fig. 2. Mean change from baseline in ALP over time by treatment group.

Fig. 2.

(A) LS mean (SE) change from baseline in serum ALP (U/L) in the DB phase (ITT population). Line at week 12 indicates dose titration. Mean baseline ALP (U/L) (SEM): 562.8 (60.0) (placebo), 422.5 (24.6) (OCA 1.5–3.0 mg), 428.5 (35.0) (OCA 5–10 mg). (B) Mean (SD) change from baseline in serum ALP in the LTSE (pooled data). Mean baseline ALP (U/L) (SD): 456.6 (224.6). ANCOVA was used for these analyses. *p <0.05; OCA dose vs. placebo. ALP, alkaline phosphatase: ANCOVA, analysis of covariance; DB, double-blind; ITT, intent-to-treat; LS, least-square; LTSE, long-term safety extension; OCA, obeticholic acid.